VANCOUVER, British Columbia and BOSTON — October 16, 2025 — Leads & Copy — Xenon Pharmaceuticals Inc. (Nasdaq: XENE) has appointed Tucker Kelly as Chief Financial Officer (CFO) and member of the senior executive team. Mr. Kelly brings strategic and commercial finance expertise to help the Company prepare for the anticipated commercialization of its lead candidate, azetukalner, which is being studied in Phase 3 programs for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD).
Ian Mortimer, President and Chief Executive Officer of Xenon, said that Mr. Kelly will be instrumental in the strategic approach to building out the necessary functions, strategies, systems, and infrastructure critical to future commercial success. Mr. Kelly said he is thrilled to join Xenon at such a critical juncture as the Company prepares to report topline results for the X-TOLE2 study and plans for the anticipated launch of azetukalner in epilepsy and beyond. He added that it is rewarding to be part of a team that has the potential to deliver life-changing therapeutics to patients.
Mr. Kelly previously served as Executive Vice President, CFO and Treasurer at Deciphera Pharmaceuticals, Inc. Prior to that, he also served as CFO of various public and private life sciences companies including AdvanDx, Inc., deCODE genetics, Inc., and Critical Therapeutics, Inc. He received a B.S. in Foreign Service from the Georgetown University School of Foreign Service and a J.D. from the University of Chicago Law School.
In connection with Mr. Kelly’s appointment, the Compensation Committee of the Company’s Board of Directors granted Mr. Kelly an option to purchase 225,000 common shares at an exercise price of $41.90 per common share and 30,000 restricted share units (RSUs).
Colleen Alabiso, Senior Vice President, Corporate Affairs, (617) 671-9238, media@xenon-pharma.com, investors@xenon-pharma.com
Source: Xenon Pharmaceuticals Inc.
